Earlier this week, chief executive of the US biotechnology company Moderna Stephane Bancel announced that they had kicked off the third phase of human trials of a vaccine against the coronavirus.

Axar.az reports citing foreign media that the Financial Times (FT) has quoted unnamed sources as saying that the US biotechnology company Moderna plans to price its COVID-19 vaccine at about $50-$60 per course.

The sources claimed that the proposed price for the mRNA-1273 vaccine would apply to the US and “other high-income countries”.
The two-dose course costs are at least $11 more than that of the US pharmaceutical giant Pfizer and its German counterpart BioNTech, which earlier clinched a deal with the US government on a $39 vaccine.